DIANT Pharma Inc

DIANT Pharma Inc. is a biopharmaceutical solutions company that specializes in the development of continuous, end-to-end manufacturing platforms for nanoparticles and lipid nanoparticles (LNPs). Founded in 2019, the company developed the proprietary DIANT Jet technology, an automated system designed to integrate nanoparticle generation with downstream operations in a closed-loop environment. By enabling precise, inline control of particle size and characteristics, this technology aims to replace traditional batch manufacturing with a more efficient, scalable, and reproducible process for the production of nucleic acid therapies, including mRNA vaccines and other advanced nanomedicines.

DIANT provides its proprietary equipment, services, and consulting to partners in the pharmaceutical, nutraceutical, and cosmetic industries, helping them de-risk and accelerate the path from research and development to commercial manufacturing. The company's platforms are built to reduce production footprints and minimize human intervention while ensuring high-quality, uniform particle formulations. DIANT’s commitment to advanced manufacturing is evidenced by its engagement with regulatory bodies, including the U.S. Food & Drug Administration, which has acquired DIANT systems for internal research, and its participation in federal innovation programs. Through these efforts, DIANT supports CDMOs and innovators in optimizing their formulation processes and improving the speed to market for complex therapeutics.